Alison Roxby, MD, MSc

Associate Professor, Medicine, Global Health

Alison Roxby MD, MSc, is an Associate Professor jointly appointed in the Departments of Medicine and Global Health. She received her MD degree from UNC-Chapel Hill and a Master’s of Science in Public Health from the London School of Hygiene and Tropical Medicine. She has worked in 5 different African countries to improve access to HIV care and prevent HIV transmission. Alison lived in Nairobi from 2009-2010, where she was a Fogarty International Clinical Research Fellow and served as the study physician for the Valacyclovir in Pregnancy trial. Alison currently holds an R01 award from NICHD titled, “Incident STIs in Kenyan Girls: a prospective cohort spanning sexual debut," and an R21 award from NIAID titled, “DMPA use and vaginal bacterial diversity among African women.” Her research studies the interaction of contraceptives and sexually transmitted infections in women. She has been heavily involved in training grants to improve representation of African colleagues in research and leadership, including co-leading a Scientific Working Group and Early stage Investigator Mentoring group with the Center for AIDS Research. She also sees adult HIV patients at Madison Clinic and is the Clinic Director of the Roosevelt Virology Clinic at UWMC. In 2020, she began to work in COVID-19 studying key populations in the King County area, including residents of nursing facilities and the workers who care for them, and joined the Coronavirus Prevention Network (CoVPN) at Fred Hutch to help ensure adequate representation of key populations in Coronavirus prevention clinical trials.

 

Publications

  1. Mda, P, Mngadi, K, Zhang, B, Burnham, R, Juraska, M, Hyrien, O et al.. Pregnancy and contraceptive use among participants of childbearing potential in the HVTN 705 HIV vaccine trial in Southern Africa. Front Reprod Health. 2025;7 :1565933. doi: 10.3389/frph.2025.1565933. PubMed PMID:40556953 PubMed Central PMC12185537.
  2. Ackerley, CG, Edupuganti, S, Yu, C, Roxby, AC, Seaton, KE, Bekker, LG et al.. Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines. Front Immunol. 2025;16 :1557009. doi: 10.3389/fimmu.2025.1557009. PubMed PMID:40438096 PubMed Central PMC12116586.
  3. Theodore, DA, Neradilek, M, Gillespie, K, Edupuganti, S, Hinojosa, JC, Lama, JR et al.. Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085. J Acquir Immune Defic Syndr. 2025;98 (4):340-345. doi: 10.1097/QAI.0000000000003582. PubMed PMID:39970314 PubMed Central PMC12375365.
  4. Chawana, TD, Walsh, SR, Stranix-Chibanda, L, Chirenje, ZM, Yu, C, Zhang, L et al.. Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV. BMC Immunol. 2025;26 (1):8. doi: 10.1186/s12865-025-00687-7. PubMed PMID:39966732 PubMed Central PMC11837431.
  5. Naicker, V, Laher, F, Bekker, LG, Seaton, KE, Allen, M, De Rosa, S et al.. Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial. PLOS Glob Public Health. 2024;4 (9):e0003319. doi: 10.1371/journal.pgph.0003319. PubMed PMID:39302924 PubMed Central PMC11414935.
Search PubMed

Comments are closed.